Trial Profile

A phase 1b trial of SAT-3247 in healthy human volunteers

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 28 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SAT 3247 (Primary)
Indications Duchenne muscular dystrophy; Muscle injury
Focus Adverse reactions

Most Recent Events

22 May 2025 Results presented in the Satellos Bioscience media release.
04 Apr 2025 Status changed from planning to recruiting.
04 Apr 2025 According to a Satellos Bioscience media release, the company initiated enrollment in phase 1b clinical trial in up to 10 adults with Duchenne muscular dystrophy (DMD) with data expected to be reported in Q2 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com